Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effects of polyphenol compounds melanin on NAFLD/NASH prevention

N. Belemets, N. Kobyliak, O. Virchenko, T. Falalyeyeva, T. Olena, P. Bodnar, O. Savchuk, T. Galenova, M. Caprnda, L. Rodrigo, L. Skladany, D. Delev, R. Opatrilova, P. Kruzliak, T. Beregova, L. Ostapchenko,

. 2017 ; 88 (-) : 267-276. [pub] 20170119

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013296

BACKGROUND: One of the pathogenic mechanisms of the progression non-alcoholic liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats. METHODS: The study was carried out on 45 Wistar rats that were divided into 3 groups: intact, MSG- and MSG+melanin groups (n=15 in each group). Newborn rats of MSG- and MSG+melanin groups were administered with MSG (4mg/g, 8μl/g, subcutaneously) at 2nd-10th days of life. Since the age of 1 month, rats of MSG-group were treated with water (0.25ml/100g), rats of MSG+melanin groups-with melanin (1mg/kg) dissolved in water (0.25ml/100g). INTRODUCTION: had been performed intermittently (two-week courses alternated with two-week breaks) for 3 months. In 4-month rats anthropometrical parameters and visceral adipose tissue (VAT) mass were estimated. To assess morphological changes in liver we used NAS (NAFLD activity score). The content of pro-inflammatory cytokines (interleukin (IL)-1β, IL-12Bp40, interferon (INF)-γ) and anti-inflammatory cytokines (IL-4, IL-10, tumor growth factor (TGF)-β) were measured by ELISA. RESULTS: We found significantly lower total score (1.0±0.19 vs 3.33±0.36, p<0.001), degree of steatosis (0.73±0.18 vs 1.80±0.17, p<0.001) and manifestation of lobular inflammation (0.27±0.11 vs 1.20±0.17, p<0.001) due to NAFLD activity score in MSG+melanin group compared to MSG-obesity. NASH we confirmed only in 33.3% of rats with MSG-obesity that was significantly higher than after melanin (6.7%) administration (p=0.033). Melanin administration reduce amount of visceral fat on 44.5% (p<0.001) as compared to MSG-obesity group. Melanin reduced the content of IL-1β in rat serum and restored the level of anti-inflammatory cytokines (IL-10, TGF-β) to the control values. CONCLUSION: Thus, the administration of melanin can prevent development of NAFLD/NASH in rats with MSG-induced obesity and can be considered as possible novel therapeutic agents but further studies to confirm its action needed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013296
003      
CZ-PrNML
005      
20170418110729.0
007      
ta
008      
170413s2017 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2017.01.028 $2 doi
035    __
$a (PubMed)28110193
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Belemets, Natalia $u Taras Shevchenko National University, Kyiv, Ukraine.
245    10
$a Effects of polyphenol compounds melanin on NAFLD/NASH prevention / $c N. Belemets, N. Kobyliak, O. Virchenko, T. Falalyeyeva, T. Olena, P. Bodnar, O. Savchuk, T. Galenova, M. Caprnda, L. Rodrigo, L. Skladany, D. Delev, R. Opatrilova, P. Kruzliak, T. Beregova, L. Ostapchenko,
520    9_
$a BACKGROUND: One of the pathogenic mechanisms of the progression non-alcoholic liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats. METHODS: The study was carried out on 45 Wistar rats that were divided into 3 groups: intact, MSG- and MSG+melanin groups (n=15 in each group). Newborn rats of MSG- and MSG+melanin groups were administered with MSG (4mg/g, 8μl/g, subcutaneously) at 2nd-10th days of life. Since the age of 1 month, rats of MSG-group were treated with water (0.25ml/100g), rats of MSG+melanin groups-with melanin (1mg/kg) dissolved in water (0.25ml/100g). INTRODUCTION: had been performed intermittently (two-week courses alternated with two-week breaks) for 3 months. In 4-month rats anthropometrical parameters and visceral adipose tissue (VAT) mass were estimated. To assess morphological changes in liver we used NAS (NAFLD activity score). The content of pro-inflammatory cytokines (interleukin (IL)-1β, IL-12Bp40, interferon (INF)-γ) and anti-inflammatory cytokines (IL-4, IL-10, tumor growth factor (TGF)-β) were measured by ELISA. RESULTS: We found significantly lower total score (1.0±0.19 vs 3.33±0.36, p<0.001), degree of steatosis (0.73±0.18 vs 1.80±0.17, p<0.001) and manifestation of lobular inflammation (0.27±0.11 vs 1.20±0.17, p<0.001) due to NAFLD activity score in MSG+melanin group compared to MSG-obesity. NASH we confirmed only in 33.3% of rats with MSG-obesity that was significantly higher than after melanin (6.7%) administration (p=0.033). Melanin administration reduce amount of visceral fat on 44.5% (p<0.001) as compared to MSG-obesity group. Melanin reduced the content of IL-1β in rat serum and restored the level of anti-inflammatory cytokines (IL-10, TGF-β) to the control values. CONCLUSION: Thus, the administration of melanin can prevent development of NAFLD/NASH in rats with MSG-induced obesity and can be considered as possible novel therapeutic agents but further studies to confirm its action needed.
650    _2
$a adipokiny $x metabolismus $7 D054392
650    _2
$a tuková tkáň $x účinky léků $x metabolismus $7 D000273
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a antioxidancia $x farmakologie $7 D000975
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a játra $x patologie $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melaniny $x farmakologie $7 D008543
650    _2
$a nealkoholová steatóza jater $x chemicky indukované $x patologie $x prevence a kontrola $7 D065626
650    _2
$a abdominální obezita $x chemicky indukované $x prevence a kontrola $7 D056128
650    _2
$a polyfenoly $x farmakologie $7 D059808
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a glutamát sodný $7 D012970
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kobyliak, Nazarii $u Bogomolets National Medical University, Kyiv, Ukraine. Electronic address: nazariikobyliak@gmail.com.
700    1_
$a Virchenko, Oleksandr $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Falalyeyeva, Tetyana $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Olena, Tsyryuk $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Bodnar, Petro $u Bogomolets National Medical University, Kyiv, Ukraine.
700    1_
$a Savchuk, Oleksiy $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Galenova, Tetyana $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Caprnda, Martin $u 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Rodrigo, Luis $u Faculty of Medicine, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
700    1_
$a Skladany, Lubomir $u Department of Internal Medicine, F. D. Roosvelt Hospital, Banska Bystrica, Slovakia.
700    1_
$a Delev, Delian $u Department Pharmacology and Clinical Pharmacology, Medical Faculty, Medical University of Plovdiv, Plovdiv, Bulgaria.
700    1_
$a Opatrilova, Radka $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia.
700    1_
$a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia; 2nd Department of Surgery, Faculty of Medicine, Masaryk University, Brno, Czechia. Electronic address: kruzliakpeter@gmail.com.
700    1_
$a Beregova, Tetyana $u Taras Shevchenko National University, Kyiv, Ukraine.
700    1_
$a Ostapchenko, Lyudmyla $u Taras Shevchenko National University, Kyiv, Ukraine.
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 88, č. - (2017), s. 267-276
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28110193 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170418111037 $b ABA008
999    __
$a ok $b bmc $g 1199761 $s 974074
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 88 $c - $d 267-276 $e 20170119 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace